Conclusion: Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab, followed by alendronate, reduce clinical fractures in postmenopausal females with osteoporosis. Abaloparatide and teriparatide increased WAEs; longer duration bisphosphonate use may increase AFF and ONJ risk though these events were rare.
PubMed 36592455 ↗Raloxifene
The short answer. There isn't much data on Raloxifene yet — 37 mentions, 9 with a clear outcome — so treat these numbers as anecdotal. It is most often used for hormones: 88% of 8 reports say that improved. It is well studied — 130 meta-analyses on PubMed.
From 37 mentions in total — the rest didn't say how it went and aren't counted.
What Raloxifene does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 130 meta-analyses on PubMed ↗ · 431 randomized trials ↗
Conclusion: Vaginal estrogen, vaginal DHEA, oral ospemifene, and vaginal moisturizers may improve some GSM symptoms in the short term. Few long-term data exist on efficacy, comparative effectiveness, tolerability, and safety of GSM treatments.
PubMed 39250810 ↗Conclusion: This review highlights that PTH1 receptor agonists effectively reduce fracture risk, with abaloparatide offering enhanced benefits for non-vertebral and hip fractures compared to teriparatide. Both agents exhibit acceptable safety profiles, suggesting their valuable role in managing osteoporosis, particularly for high-risk patients.
PubMed 40047881 ↗Conclusion: Finally, denosumab was not associated with improvement in safety outcomes, compared to placebo. These findings should be interpreted with caution as some analyses suffered from statistical imprecision.
PubMed 37016189 ↗86 human trials on ClinicalTrials.gov test Raloxifene — 72 completed, 4 recruiting now. See all on ClinicalTrials.gov ↗
- ER Reactivation Therapy for Breast Cancer · Metastatic Breast Cancer · 2024
- Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database · Breast Cancer · 2024
- Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome · Polycystic Ovary Syndrome · 2009
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
Boxed warning (the FDA's strongest label warning): “INCREASED RISK OF VENOUS THROMBOEMBOLISM AND DEATH FROM STROKE Increased risk of deep vein thrombosis and pulmonary embolism have been reported with raloxifene hydrochloride. Women with active or past history of venous thromboembolism should not take raloxifene hydrochloride. Increased risk of…”
2 recalls of products named for Raloxifene. Most recent:
- 2020-02-19 · Class II: Failed Dissolution Specifications: Low out of specification results obtained during stability testing. record ↗
- 2014-01-29 · Class II: Labeling: Label Mixup: RALOXIFENE HCL, Tablet, 60 mg may be potentially mis-labeled as following drug: ISOSORBIDE MONONITRATE, Tablet, 20 mg, NDC… record ↗
Class I = could cause serious harm; Class II = temporary or reversible harm; Class III = unlikely to cause harm. Recalls are of specific products and lots, not of the ingredient itself. All recalls (openFDA) ↗
16,046 adverse-event reports mention Raloxifene. Most often reported:
- Nausea · 848
- Fall · 830
- Drug ineffective · 828
- Pain in extremity · 767
- Pain · 740
- Arthralgia · 704
Reports often involve several drugs and serious illness; a report doesn't prove the drug caused the problem, and these counts can't tell you how often it happens. Source query (openFDA) ↗
NIH has funded 30 research projects with Raloxifene in the title, $11,579,933 in total (1995–2025). NIH RePORTER ↗
Plain-language guides from the US government: MedlinePlus: Raloxifene ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I experienced this running the same stack. Ran a full regiment of Raloxifene and reversed it entirely.”
“the rolax has slowed down the gyno but I still feel it getting bigger.”
“I tried 5 weeks of Ralox and it didn't really work”
“What I did was dose 30mg from the start of an 8 week rad cycle. Then just did it for an extra 4-8 weeks after the cycle and it was gone.”
Top discussions (5)
- How to get rid of moobs? ↗
- Recreational ways to remove Gynecomastia Fibrous Tissue ↗
- Whenever I take my Mega B Complex my depression lifts almost instantly. Like everything seems brighter, happier, and my energy increases. Could I be deficient? ↗
- MK-677 Primer ↗
- Some specific doubts about ashwgandha KSM-66 ↗
Raloxifene compared
Other options for hormones
Sources
- User reports: 37 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- FDA drug label (DailyMed) ↗
- FDA adverse-event reports (FAERS) ↗
- FDA recalls ↗
- MedlinePlus (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate